In Challenging Times, Sanofi’s Viehbacher Explores New Pricing Models In Emerging Markets

 
• By Vikas Dandekar

In a rare spotlight opportunity, Sanofi CEO Christopher Viehbacher shares his views on emerging markets during a visit to Mumbai.

MUMBAI – Sanofi CEO Christopher Viehbacher visited India on Monday, Sept. 30, at a time when the industry faces tough challenges in emerging markets, be it pricing pressures and graft charges in China, or the impact of India’s new drug pricing policy.

Viehbacher delivered a keynote address during the 47th Annual General Meeting of the Organization of Pharmaceutical Producers of India, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.